FDA Approval of Nereus Sends Vanda Shares Up 30%
Vanda’s shares surged 30% after the FDA approved Nereus for preventing motion-induced vomiting. The approval establishes a potential new indication to treat nausea from GLP-1 weight-loss therapies, expanding Vanda’s addressable market and reinforcing its late-stage product pipeline.
1. FDA Approval of Nereus Unlocks New Indication
In December 2025 Vanda Pharmaceuticals secured FDA approval for Nereus, its orally administered treatment for motion sickness. Analysts project initial Nereus prescriptions to reach 30,000 in the first full year of launch, driven by an estimated addressable patient pool of 25 million U.S. travelers prone to motion-induced nausea. Beyond the core indication, Vanda has initiated a Phase II trial evaluating Nereus for nausea linked to GLP-1 receptor agonists, a market estimated at $2 billion annually. The broad antiemetic label and differentiated receptor profile position Nereus to capture share from off-label antiemetics, with peak sales forecasts ranging from $150 million to $200 million by 2028.
2. Q3 Financials Reflect Strategic Investment Phase
During Q3 2025, Vanda reported Fanapt revenue growth of 18% year-over-year, driven by expanded formulary access and increased prescribing in outpatient psychiatric clinics. Despite this top-line growth, the company recorded a net loss of $22.6 million, compared with a loss of $8.4 million in the prior-year quarter. The wider loss reflected a 45% jump in R&D expenses—up to $30.2 million—primarily to support ongoing late-stage trials, and a 35% rise in SG&A to $25.8 million for prelaunch commercial activities. Management emphasized that these one-time investments will underpin multiple product launches over the next 18 months.
3. Strong Balance Sheet and 2026 Catalysts
As of September 30, Vanda held $293.8 million in cash and marketable securities, providing a runway through 2027 without the need for near-term equity or debt financing. For full-year 2025, management reiterated revenue guidance of $210 million to $230 million, reflecting contributions from Fanapt and early Nereus sales. Looking ahead to 2026, investors are focused on the April PDUFA decision for Bysanti in chemotherapy-induced nausea and the commercial roll-out of Nereus, milestones that could drive a substantial re-rating if successful. The combination of multiple regulatory readouts and the scalable U.S. commercial infrastructure supports the firm’s buy rating in the view of several brokerage analysts.